Which Business Actions Trigger Tortious Interference Claims in Medicine?

Intent in tortious interference does not require malice or personal animosity. Instead, courts examine whether the defendant acted with knowledge that interference was substantially certain to result from its conduct. In medicine law disputes, this often involves scrutiny of communications, competitive strategies, and whether the corporation targeted a specific relationship or simply pursued lawful market competition. From a practitioner's perspective, the distinction between knowledge and mere foresight becomes critical during discovery, as internal emails and business records frequently reveal the defendant's state of mind at the time of the contested conduct.

Courts recognize a qualified privilege for legitimate competitive conduct, even if it incidentally interferes with another party's relationships. A corporation may lawfully compete for customers, recruit employees, or develop superior products without liability, provided the means are not independently tortious (such as fraud, defamation, or breach of confidentiality). In healthcare settings, this privilege extends to truthful marketing, clinical research disclosures, and good-faith business negotiations. The question becomes whether the corporation's actions served a legitimate business interest and whether the methods employed were consistent with industry norms and applicable law.

Improper conduct may include inducing breach of contract through false statements, misrepresenting credentials or regulatory status, violating confidentiality obligations, or exploiting a fiduciary relationship. In the pharmaceutical and medical device sectors, improper conduct can also encompass off-label marketing claims, kickback schemes, or anti-competitive practices that violate federal law. The Restatement (Second) of Torts identifies factors courts weigh: whether the defendant's conduct was independently wrongful, the nature of the defendant's interest, the extent to which the defendant's conduct was motivated by a desire to harm the plaintiff versus pursuit of legitimate gain, and the social interest in protecting the plaintiff's relationship. These factors do not follow a rigid hierarchy; courts balance them according to the specific factual and legal context.

Tortious interference claims often proceed alongside breach of contract or regulatory violation claims, complicating discovery and motion practice. In New York state courts handling complex commercial disputes, delayed production of business communications, incomplete privilege logs, or inadequate preservation of electronic records can prejudice a corporation's defense and invite adverse inferences about state of mind. A corporation defending such a claim should ensure contemporaneous documentation of legitimate business decisions, preserve communications showing the absence of knowledge or intent to interfere, and establish that any market disruption resulted from lawful competitive advantage rather than improper interference. Courts may also consider whether a corporation's conduct violated professional licensing rules, anti-kickback statutes, or FDA regulations, as such violations can support a finding of improper conduct even if the plaintiff cannot prove the traditional tort elements.

While unlawful eviction claims involve direct property law violations, tortious interference focuses on interference with contractual or prospective economic relations. A corporation might face both types of claims if, for example, it pressures a landlord to terminate a tenant's lease (potential unlawful eviction exposure) while also interfering with the tenant's business relationships (tortious interference). The statutory protections afforded to tenants under New York law operate independently of tortious interference doctrine, meaning a corporation cannot simply argue that its conduct was just business if it violates housing law or other protective statutes. Courts examine the full spectrum of the defendant's conduct when assessing whether improper means were employed.

A corporation should evaluate tortious interference exposure whenever it undertakes aggressive market entry, recruits key employees from competitors, acquires contracts from another vendor, or makes public statements about a competitor's products or practices in the healthcare sector. Risk assessment should occur before the conduct, not after a lawsuit is filed. This means documenting the business rationale for competitive decisions, ensuring that marketing claims are truthful and substantiated, reviewing employee non-compete and confidentiality agreements, and confirming that no inducement to breach is occurring. Tortious interference liability can extend to multiple actors within a corporation (employees, managers, board members), so internal compliance training and clear policies on competitive conduct are valuable risk mitigation tools.